Navigation Links
Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
Date:1/28/2010

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers. In its Addiction program, Omeros is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists for the prevention and treatment of addiction to substances of abuse, such as opioids, nicotine and alcohol, as well as other compulsive behaviors, including eating disorders. The Company's data from earlier European pilot clinical studies and animal models of addiction have demonstrated a previously unknown link between PPAR-gamma and addiction disorders.

Under the agreement, the New York State Psychiatric Institute researchers, led by Dr. Sandra D. Comer, will conduct a Phase 2 clinical study to evaluate a PPAR-gamma agonist in the treatment of addiction to opioids, expected to begin enrollment in the first half of this year. The study will be managed through the Research Foundation for Mental Hygiene (RFMH). The responsibilities of RFMH also include the filing of the related investigational new drug application (IND) with the Food and Drug Administration (FDA). Funding of substantially all of the costs of this study, including the regulatory costs, will be provided to RFMH through a grant from NIDA. Omeros will have the right to reference the data obtained from this study for subsequent submissions to the FDA and will retain all other rights in connection with its Addiction
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daniel K. Spiegelman Elected to Board of Directors of Omeros
2. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
3. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
4. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
5. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
6. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
7. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
8. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
10. CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer
11. NeuIsys Announces Entrance into the Gastroenterology Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 NxStage Medical, Inc. (Nasdaq: NXTM ... reported first quarter financial results that exceed the top ... for the first quarter of 2015 increased 10 percent ... for the first quarter of 2014. The Company,s revenue ... to $78.5 million.  The increase was driven by outperformance ...
(Date:5/6/2015)... , May 6, 2015  IGI Laboratories, Inc. (NYSE-MKT: IG), ... pharmaceutical company, will be presenting today at the Deutsche Bank ... on May 6 th and 7 th at ... Jason Grenfell-Gardner , CEO and President and ... will present today, May 6, 2015, at 3:30 p.m. ET.   ...
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
... Data presented yesterday showed that USL255, a novel ... less fluctuation in topiramate plasma levels than immediate-release ... These and other findings from the USL255 early ... the 64th annual American Epilepsy Society (AES) meeting ...
... Dec. 6, 2010 The Novartis Pharmaceutical Corporation ... disease control and tumor reduction in extensively pretreated ... become refractory after an autologous stem cell transplant, ... clinical trial presented today(1). In this ...
Cached Medicine Technology:Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 2Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 3Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7
(Date:5/6/2015)... The Beryl Institute announces the publication of ... Journal (PXJ), an international, open access, peer-reviewed journal focused ... patient experience. The second volume of PXJ supports the ... align the voices engaged and provides the space for ... with The Beryl Institute, Volume 2, Issue 1 includes ...
(Date:5/6/2015)... Denver, Colorado (PRWEB) May 06, 2015 ... own success? , Next month the Centennial State will ... legal, recreational cannabis sales to adults. And while Colorado’s ... rapid growth during that time, it’s also facing some ... the state are currently facing shortages, especially in the ...
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 vcfo, ... finance, HR, IT and operational support to optimize business ... Consulting CFOs, Jack Lynch and Michael Scheaffer. Both Lynch ... finance and leadership experience. , “We are delighted ... Ellen Wood, vcfo CEO. “Leveraging their background in financial ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup established ... successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction system (qPCR) ... qPCR is shown to be capable of detecting several ... C, and E. Coli. This qPCR system has achieved ... 9 orders of magnitude dynamic range. A key ...
(Date:5/6/2015)... Manassas, VA (PRWEB) May 06, 2015 Locally ... Oil, LLC, was recognized this past week as having one ... The company’s EVOO, imported from the Peloponnese region of Greece ... Gold Award in the category of Medium Olive Oil, ... EVOO for everyday use”. With over 700 producer applicants ...
Breaking Medicine News(10 mins):Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2
... Brazil- Tumor progression is usually ensured by more than ... down by a specifically targeted drug, other mechanisms may ... they may also become an opportunity for researchers to ... paper recently published in the journal Oncology ...
... Ala. People in minority groups, especially black Americans, ... their personal financial resources to prolong life after being ... University of Alabama at Birmingham study published April 26, ... the American Cancer Society. This revelation should inform ...
... By Steven Reinberg HealthDay Reporter , ... such as ibuprofen, aspirin and naproxen may reduce the ... SSRIs, according to a mouse and human study from ... -- which are the most common antidepressants and ...
... Reporter , MONDAY, April 25 (HealthDay News) -- Elementary school ... the bullies themselves -- made more frequent visits to a ... than their other classmates, according to new research out of ... frequent stomachaches from being picked on," said Eric Vernberg, lead ...
... In a paper published in the April 25 early ... Academy of Sciences, researchers at the University of ... in San Francisco and colleagues report a game-changing advance ... primitive neural precursor cells from human embryonic stem cells ...
... , MONDAY, April 25 (HealthDay News) -- Music lessons ... a new study suggests. Researchers from the University of ... 83, into three groups based on their amount of musical ... lessons, and at least 10 years of musical study. ...
Cached Medicine News:Health News:A potential novel drug-target for colorectal cancer treatment comes from the brain 2Health News:Blacks more willing to exhaust financial resources for more cancer care 2Health News: Common Painkillers May Blunt Antidepressants 2Health News: Common Painkillers May Blunt Antidepressants 3Health News:Bullied Kids Showing Up in School Nurses' Offices 2Health News:Bullied Kids Showing Up in School Nurses' Offices 3Health News:Scientists create stable, self-renewing neural stem cells 2Health News:Music Training May Help Keep Aging Brain Healthy 2
... of the benefits and functionality of ... additional feature of being able to ... for importing and storage of up ... This additional feature allows for complete ...
Inquire...
Inquire...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Medicine Products: